ES2333522T3 - Tratamiento y prevencion del daño tisular asociado a la produccion de proteina c-reactiva aumentada. - Google Patents

Tratamiento y prevencion del daño tisular asociado a la produccion de proteina c-reactiva aumentada. Download PDF

Info

Publication number
ES2333522T3
ES2333522T3 ES03727670T ES03727670T ES2333522T3 ES 2333522 T3 ES2333522 T3 ES 2333522T3 ES 03727670 T ES03727670 T ES 03727670T ES 03727670 T ES03727670 T ES 03727670T ES 2333522 T3 ES2333522 T3 ES 2333522T3
Authority
ES
Spain
Prior art keywords
crp
ligand
linker
agent
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03727670T
Other languages
English (en)
Spanish (es)
Inventor
Mark B. Pepys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentraxin Therapeutics Ltd
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Application granted granted Critical
Publication of ES2333522T3 publication Critical patent/ES2333522T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
ES03727670T 2002-05-15 2003-05-14 Tratamiento y prevencion del daño tisular asociado a la produccion de proteina c-reactiva aumentada. Expired - Lifetime ES2333522T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211136.7A GB0211136D0 (en) 2002-05-15 2002-05-15 Treatment and prevention of tissue damage
GB0211136 2002-05-15

Publications (1)

Publication Number Publication Date
ES2333522T3 true ES2333522T3 (es) 2010-02-23

Family

ID=9936726

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03727670T Expired - Lifetime ES2333522T3 (es) 2002-05-15 2003-05-14 Tratamiento y prevencion del daño tisular asociado a la produccion de proteina c-reactiva aumentada.

Country Status (11)

Country Link
US (1) US7615543B2 (enExample)
EP (1) EP1503800B1 (enExample)
JP (2) JP2005531559A (enExample)
AT (1) ATE446761T1 (enExample)
AU (1) AU2003234000B8 (enExample)
CA (1) CA2485852C (enExample)
DE (1) DE60329839D1 (enExample)
DK (1) DK1503800T3 (enExample)
ES (1) ES2333522T3 (enExample)
GB (1) GB0211136D0 (enExample)
WO (1) WO2003097104A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
CN101845009B (zh) 2002-07-29 2012-10-03 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
PT1596880E (pt) 2002-12-23 2011-06-06 Univ Rice William M Métodos e composições para suprimir a diferenciação de fibrócitos
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
GB0313386D0 (en) * 2003-06-10 2003-07-16 Univ London Treatment of disease
US20070265196A1 (en) * 2004-01-21 2007-11-15 Medvet Science Pty., Ltd. Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
EP1582527A1 (en) * 2004-03-31 2005-10-05 Ciba SC Holding AG Synthesis of phosphorus based ligands
CA2654440C (en) * 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
ES2409756T3 (es) 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2405929B1 (en) 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
US8674027B2 (en) 2009-09-18 2014-03-18 Dow Global Technologies Llc Powdered thermoplastic polyolefin elastomer composition for slush molding processes
WO2011155956A1 (en) 2010-06-08 2011-12-15 Dow Global Technologies Llc Polyolefin elastomer composition for artificial leather applications
US20150087576A1 (en) * 2011-12-14 2015-03-26 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap)
EP2890300B1 (en) 2012-08-31 2019-01-02 Kenji Suzuki Supervised machine learning technique for reduction of radiation dose in computed tomography imaging
EP2957563A1 (en) * 2014-06-19 2015-12-23 Pentracor GmbH Separation material comprising phosphoryl choline derivatives
GB202002299D0 (en) * 2020-02-19 2020-04-01 Pentraxin Therapeutics Ltd Agents for use in the treatment of tissue damage
WO2021197371A1 (zh) * 2020-03-31 2021-10-07 南京金斯瑞生物科技有限公司 一种含有刚性连接子的生物偶联物
WO2022178594A1 (en) * 2021-02-25 2022-09-01 Baker Heart and Diabetes Institute C-reactive protein inhibitors
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage
KR20230060368A (ko) * 2021-10-27 2023-05-04 솔브레인 주식회사 환형 포스핀 화합물의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640913A (en) 1983-01-10 1987-02-03 American Cyanamid Company Phosphocholine derivatives having antihypertensive action
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5811568A (en) 1992-10-08 1998-09-22 Shaman Pharmaceuticals, Inc. Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
US5681829A (en) 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
JP4524846B2 (ja) 2000-04-20 2010-08-18 日油株式会社 化粧料
US6764826B2 (en) 2000-06-08 2004-07-20 Board Of Regents, The University Of Texas System Inhibitors of C-reactive protein induced inflammation
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
JP4472333B2 (ja) 2001-08-08 2010-06-02 ペントラキシン セラピューティクス リミテッド 好ましくないタンパク質群を患者の血漿から除去するための薬剤
GB0211136D0 (en) * 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage

Also Published As

Publication number Publication date
JP2010174013A (ja) 2010-08-12
CA2485852A1 (en) 2003-11-27
ATE446761T1 (de) 2009-11-15
GB0211136D0 (en) 2002-06-26
DK1503800T3 (da) 2010-02-01
AU2003234000B8 (en) 2008-07-31
DE60329839D1 (de) 2009-12-10
AU2003234000A1 (en) 2003-12-02
US7615543B2 (en) 2009-11-10
JP2005531559A (ja) 2005-10-20
WO2003097104A1 (en) 2003-11-27
EP1503800A1 (en) 2005-02-09
AU2003234000B2 (en) 2008-06-05
CA2485852C (en) 2012-01-17
EP1503800B1 (en) 2009-10-28
US20060019930A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ES2333522T3 (es) Tratamiento y prevencion del daño tisular asociado a la produccion de proteina c-reactiva aumentada.
US8039222B2 (en) Treatment and prevention of tissue damage
AU762991B2 (en) Molecules that home to various selected organs or tissues
JP5597543B2 (ja) 糖衣の幅を決定する方法およびプログラム
ES2396368T3 (es) Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
Elvas et al. Phosphatidylethanolamine targeting for cell death imaging in early treatment response evaluation and disease diagnosis
JP2018048139A (ja) 治療用ペプチド
PT906426E (pt) Anticorpos para o domínio ed-b de fibronectina, sua construção e utilizações
JP2005531559A5 (enExample)
KR20120042731A (ko) 항체 표적화 화합물
ES3057215T3 (en) Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
US20140371079A1 (en) Cancer-targeting peptides and uses thereof in cancer treatment and diagnonsis
WO1999040837A2 (en) Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20130336894A1 (en) Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
KR20040034584A (ko) 교란된 막 결합 화합물
ES2671522T3 (es) Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
US20090170749A1 (en) Novel Compounds Which Interact With PEA-15
WO2021002771A1 (en) Conjugate of fluorescent dye for the visualization of psma expressing cells
EP1051196A2 (en) Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20120264212A1 (en) Compounds and methods for inhibiting the metastasis of cancer cells
WO2021053185A1 (en) Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
Zeller et al. Discovery, in-vitro and in-vivo efficacy of an anti-inflammatory small molecule inhibitor of C-reactive protein
Klegerman Targeting Liposomes to Metastatic Tumors with Antibodies Specific for VCAM-1
WO2025006536A2 (en) Factor xii binding peptides and methods of use
JP2019076117A (ja) 血管新生関連疾患の治療又は予防剤のスクリーニング方法